AOK PLUS Die Gesundheitskasse F R Sachsen Und Th Ringen Tender

Contract notice: conclusion of non-exclusive drug discount agreements according to § 130a para. 8 sgb v by way of a so-called open-house model for the active ingredient etanercept (atc code according to who: l04ab01) The subject of this publication is the conclusion of non-exclusive discount agreements according to § 130a para. 8 sgb v on drugs with the active ingredient etanercept (atc code according to who: l04ab01. the contract is concluded as part of a so-called open-house model, i.E. a contract is open to all interested pharmaceutical companies within the participation period, provided they meet the participation requirements and accept. this has the consequence that individual contract negotiations are not conducted and (delivery) exclusivity does not exist. it is pointed out that the purchase quantity is unknown, since this depends on the demand and the development of the insured number, on the prescription behavior of the doctors as well as the sales and storage behavior of the public pharmacies. minimum purchase quantities are therefore not guaranteed. for further information, please refer to point ii.2.4) of the announcement.Interested pharmaceutical entrepreneurs can download the participation documents via the project space of the german procurement portal (dtvp). an application for access to the project room is required first. after activation by the client, the participation documents can then be accessed. as a scan by e-mail or electronically signed by e-mail) to the address given under i.1). all other submission deadlines can be found in the attachment "submission deadlines" in the project room. to meet the deadline, timely receipt of the participation application by the client as a scan via e-mail or electronically signed via e-mail is sufficient; the original written contracts must be submitted immediately. if the submission deadline falls on a saturday, sunday or national public holiday, the next working day takes the place of such a day. in the case of late receipt, the submitted applications for participation will be considered at the next submission deadline. the client reserves the right to request the pharmaceutical companies to submit, complete or correct missing, incomplete or incorrect documents (in particular declarations, information and evidence) (additional request), while complying with the principles of transparency and equal treatment. the documents are to be submitted by the pharmaceutical company at the request of the client within a period determined by the calendar. if the required documents are not submitted within the deadline, the application for participation can be excluded or only considered at the next submission deadline. the discount agreement ends, regardless of the date of the conclusion of the contract, by 03/31/2024 at the latest. the client reserves the right to use the open-house procedure to terminate prematurely, in particular in the case of the conclusion of exclusive discount agreements; in